Semax Human Studies: What Has Actually Been Tested in People?

Semax is marketed online as a nootropic peptide that sharpens focus, protects the brain, speeds stroke recovery, and even relieves migraines. Much of that marketing leans on the fact that Semax has a genuine, decades-long research history in Russia, where it is sold as nasal drops. That history is real, but it is also different from what most peptide research looks like: it is heavy on animal experiments, thin on modern controlled human trials, and scattered across Russian-language journals that are hard for an English-speaking reader to independently check. This article works through the Semax human research record claim by claim, study by study.

In July 2026, an FDA advisory committee reviewed Semax free base and Semax acetate for possible inclusion on the pharmacy-compounding bulk drug substances list. The committee voted to recommend inclusion, but that vote came after the FDA's own scientific staff had already concluded that the evidence weighed against it, and the recommendation itself does not make Semax an FDA-approved medication. This article sets the marketing claims aside and looks directly at what has been tested in people: healthy-volunteer studies, stroke studies, brain-imaging studies, migraine and facial-pain research, the Russian-language literature that is difficult to evaluate from the outside, and the animal studies that frequently get presented online as if they were conducted in humans.

The key point: the FDA's own reviewers found the available Semax evidence insufficient to support its nominated uses of cerebral ischemia, migraine, and trigeminal neuralgia, and identified no human pharmacokinetic studies and no human safety data for the injectable form sold online. Most of the specific, human-sounding claims attached to Semax, such as increased BDNF, protected neurons, and improved memory, trace back to rats and mice, not to people. Where human studies do exist, they are almost all small, short, and missing the placebo control or blinding that would let an independent reader trust the result.

How Many Direct Human Semax Studies Actually Exist?

There is no single comprehensive, independently conducted systematic review of Semax human trials comparable to what exists for some other peptides. What is publicly available is a patchwork: a handful of small studies in healthy volunteers, a small number of stroke studies from Russian clinical centers, two modern brain-imaging studies, one old and frequently cited pain study, and a much larger body of animal research that is often summarized alongside the human findings in ways that blur the line between the two. The FDA briefing document for Semax reached a similar conclusion from the regulatory side: after reviewing the available literature, FDA staff found the human evidence insufficient for every proposed use and noted that a meaningful share of the cited research was published only in Russian or lacked enough English-language detail for a full evaluation.

Healthy-Volunteer Studies

The study most often cited to support Semax as a cognitive enhancer is a 1996 report by Kaplan and colleagues at Moscow State University, Synthetic ACTH Analogue Semax Displays Nootropic-Like Activity in Humans. It combined two small experiments. In the first, nine healthy male volunteers received intranasal Semax and had their EEG recorded before and after brief hyperventilation, a way of testing the peptide's effect on brain activity during temporarily reduced blood flow. In the second, eleven healthy young male volunteers (ages 23 to 27) received intranasal Semax (0.25 to 1.0 mg, roughly 4 to 16 micrograms per kilogram of body weight) during an eight-hour work shift and were tested on selective attention and short-term memory before and after mentally fatiguing work. The authors reported that Semax improved performance on some attention and memory measures, with the largest effects in fatigued subjects, and that the benefit was still detectable the next morning.

That is a real, published human finding, and it is also a nearly thirty-year-old study of twenty total participants, all young men, in a single research group, with no independent replication in an English-language journal that has surfaced since. A short-term attention-test improvement in twenty fatigued young men during one work shift does not establish that Semax reliably improves memory, focus, or productivity in a broader population, and no larger, independently run, placebo-controlled trial has replicated it.

Stroke Studies

Semax's clinical use in Russia centers on ischemic stroke, and this is the area with the most human data, but the data have real limits. A 1996 report, Effectiveness of Semax in the Acute Period of Hemispheric Ischemic Stroke, describes 30 patients who received Semax during the acute period after a stroke, compared against 80 patients who received conventional therapy alone, with EEG and evoked-potential monitoring. The authors reported that adding Semax was associated with faster resolution of some neurological deficits, with the most effective doses identified as 12 milligrams per day for moderate strokes and 18 milligrams per day for severe strokes. The published abstract does not describe how patients were assigned to each group, whether assessors were blinded, or whether the two groups were otherwise comparable, which are the details needed to know whether Semax caused the difference or whether the groups simply differed going in.

A more recent study, The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke, examined 110 stroke patients split into early- and late-rehabilitation groups, with each group further divided into those who did and did not receive Semax. Semax use was associated with higher plasma BDNF levels and better Barthel Index and motor-performance scores. This study measured genuinely clinically relevant outcomes, disability and motor function, not just a lab value, but patients were not randomly assigned to the Semax and non-Semax subgroups. That design can show an association; it cannot rule out that the patients who received Semax also differed in other ways, such as overall stroke severity or the rehabilitation they received.

Semax should never be used as a substitute for emergency stroke treatment. Sudden facial drooping, arm weakness, slurred speech, severe imbalance, or a sudden severe headache require immediate emergency care; the National Institute of Neurological Disorders and Stroke explains why acting quickly changes outcomes.

Brain-Imaging Studies

Two modern, better-controlled human studies used functional MRI to look at Semax's effect on brain activity, and both are frequently cited as evidence that Semax "works" on the brain. Neither measured memory, attention, or any behavioral outcome.

Effects of Semax on the Default Mode Network of the Brain (Lebedeva et al., 2018) studied 24 healthy adults, 14 who received intranasal 1% Semax and 10 who received placebo, with resting-state fMRI performed immediately before dosing and again 5 and 20 minutes later. The Semax group showed a larger volume in the rostral, medial-frontal subcomponent of the default mode network, a resting-state brain network involved in internally directed thought, compared with the placebo group. That is a real, controlled finding, and it is also exactly what it sounds like: a change in the size of a network on a brain scan, measured within twenty minutes of a single dose, in 24 healthy people who were not tested on any memory, attention, or productivity task at all. A short-term shift in resting-state connectivity is not equivalent to demonstrating better memory, better productivity, or long-term cognitive health, and this study was not designed to show any of those things.

Functional Connectomic Approach to Studying Selank and Semax Effects (Panikratova et al., 2020) studied 52 healthy participants split roughly evenly between Semax, the related peptide Selank, and placebo, again with resting-state fMRI before dosing and 5 and 20 minutes after. Researchers found changes in functional connectivity between the right amygdala and regions of the right temporal cortex, with some effects shared between Semax and Selank and some specific to one or the other. Again, this measured connectivity between brain regions on a scan, not any cognitive or emotional outcome in the participants' actual lives.

Both studies are legitimate contributions to understanding how Semax might act on the brain, and both are commonly stretched online into claims the authors never made. A brain-imaging change is a hypothesis-generating result, not proof of a clinical benefit.

Migraine and Facial-Pain Research

The human evidence for migraine and facial pain is thinner than for stroke. The primary source is a 1996 paper, Analgesic Action of the New Drug Semax, which reported that intranasal Semax (0.5 mg/kg) relieved migraine headache and pain from dental plexalgia, a facial-pain condition. According to the FDA's review of this and related material, roughly 12 adults with migraine received a single intranasal dose; four reportedly had their headache resolve within 90 to 120 minutes, while the other eight had partial, incomplete relief. There was no placebo group and no blinding, so it is not possible to know how many of those participants would have improved on their own. A separate, small, uncontrolled portion of the research looked at typical trigeminal neuralgia specifically and found no meaningful improvement; only the distinct dental-plexalgia subgroup showed a reported benefit.

The FDA concluded that the evidence was insufficient to support Semax for either migraine or trigeminal neuralgia. Migraine and trigeminal neuralgia are both conditions with established, evidence-based treatments; the National Institute of Neurological Disorders and Stroke is a useful starting point for what those treatments are.

Russian-Language Studies That Are Difficult to Independently Evaluate

A recurring problem runs through almost every Semax study described above: much of the underlying clinical work was originally published in Russian-language journals, sometimes as short communications or conference abstracts, with only a brief English abstract, if any, available to outside reviewers. The FDA's own briefing document flagged this directly, noting that several of the references submitted in support of Semax did not include sufficient English-language information for a complete evaluation.

A concrete example: Russian-language secondary sources describe a randomized, double-blind, placebo-controlled trial of intranasal Semax (12 to 18 mg per day for 5 days) in patients with first-time carotid ischemic stroke, reporting that the treatment was safe, well tolerated, and free of significant side effects. If accurately described, that would be a meaningfully stronger study design than most of the English-indexed Semax literature. The trouble is that an English-speaking reader cannot verify the randomization method, the blinding procedure, the statistical analysis, or the full results without a complete, faithful translation of the original methods and data, none of which is readily available. This is the core issue with the Russian-language Semax literature as a whole: it is not that the research is necessarily poor, it is that independent, English-language verification is often not possible, which means claims resting on it should be treated as unconfirmed rather than established.

Animal Studies Presented Online As Human Evidence

The large majority of Semax's mechanistic research, and a good share of the specific claims repeated in marketing copy, comes from rats and mice, not people. A detailed 2013 review by researchers at Russia's Institute of Molecular Genetics, A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides, catalogs this animal literature at length, including:

• Increased brain-derived neurotrophic factor (BDNF): Intranasal Semax increased BDNF protein levels in the rat basal forebrain within three hours of dosing (see the basal forebrain study), and a separate study found increased BDNF and TrkB receptor activity in the rat hippocampus, alongside improved performance on a passive-avoidance learning task (see the hippocampus and TrkB study). These are the studies most often cited as "Semax increases BDNF," almost always without mentioning that the animals were rats.
• Learning and memory tasks: Semax accelerated rats' acquisition of food-related tasks in a T-maze and improved performance on the conditioned passive-avoidance reflex, a standard rodent memory test, at specific dose ranges.
• Stroke and ischemia models: In rats, Semax reduced neurological damage after experimentally induced cerebral ischemia from gravitational overload, improved outcomes in a photothrombotic stroke model, and reduced markers of oxidative stress after induced ischemia.
• Hypoxia survival: Semax increased rats' survival time and resistance during experimentally induced low-oxygen conditions, including simulated high-altitude exposure.
• A rat model of "clinical death": Rats revived after induced cardiac arrest and given daily intranasal Semax showed more normal exploratory behavior afterward than untreated revived rats.

Each of these is a legitimate, published animal finding, and each one describes a controlled laboratory experiment in rodents, not a demonstrated effect in people. Rat dosing, rat brain anatomy, and a rat's performance on a maze do not translate directly to a human dose, a human brain, or a human's memory or productivity. When a Semax product page cites "increases BDNF" or "protects neurons" without saying the underlying study was conducted in animals, it is presenting animal biology as though it were human evidence.

Outcomes Measured Versus Benefits Commonly Advertised

Lining up what was actually measured against what gets advertised is one of the clearest ways to see the gap:

What was measured: EEG spectral changes and a short-term attention or memory-test score in about 20 healthy young men (1996); plasma BDNF levels, a motor-performance scale, and the Barthel Index (a disability measure) in stroke patients, in a non-randomized comparison; the volume of one resting-state brain network, or connectivity between two brain regions, measured by fMRI within 20 minutes of a single dose in 24 to 52 healthy adults; a single-dose pain-rating change in roughly 12 people with migraine, with no placebo group.

What is commonly advertised: enhanced memory, focus, and productivity comparable to prescription stimulants; a safe, natural alternative for ADHD; meaningful acceleration of stroke recovery; effective migraine and facial-pain relief; general neuroprotection and long-term brain health; safety for repeated, long-term intranasal or injectable use.

None of the studies above measured daily productivity, workplace performance, ADHD symptoms, long-term cognitive health, or long-term safety with repeated use. A change in a brain scan, an EEG pattern, or a lab value is a measurement that a study can reasonably make; a claim about how someone will feel or perform in daily life is a different, larger claim that these particular studies were not designed to answer.

Why Independent Replication Matters

Nearly every human Semax study described here shares at least one significant limitation: a small sample, a missing placebo group, unclear blinding, a non-randomized comparison, or a level of detail that cannot be fully verified in English. None of that means the underlying biology is fake or that the research is worthless. It means that no single study, and no collection of small, differently limited studies from a small number of overlapping research groups, can substitute for what independent replication is meant to provide: a check on whether an original finding holds up when a different team, with no stake in the result, tries to reproduce it under rigorous, blinded, placebo-controlled conditions. That kind of independent, large-scale replication has not happened for Semax in cognition, stroke recovery, migraine, or trigeminal neuralgia, which is a meaningful part of why the FDA's own scientific staff concluded that the evidence was insufficient for each of Semax's proposed uses.

The Bottom Line

Semax has more human research behind it than many peptides sold online, and that research is not nothing: a small controlled study did find attention and memory changes in fatigued young men, two modern fMRI studies did find real changes in brain connectivity after a single dose, and stroke patients given Semax alongside standard care have shown better biomarker and functional scores in non-randomized comparisons. What the evidence does not currently show is that Semax reliably improves cognition, meaningfully speeds stroke recovery, or treats migraine or trigeminal neuralgia in a way that has been confirmed through adequately designed, independently replicated human trials. Much of what circulates online as "proof" is either a decades-old study of twenty people, a brain scan with no behavioral outcome attached, a single uncontrolled pain study, or a rodent experiment described in language that makes it sound like it happened in a person.

For a broader look at Semax's proposed benefits, documented risks, and the FDA's full 2026 review, see AlphaMD's Semax benefits, risks, and side effects overview.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Semax is not currently an FDA-approved drug. Speak with a licensed medical provider before using any medication, peptide, supplement, nasal product, or injectable substance.